“We clearly have very strong positions in psych and migraine and emerging leadership position in Parkinson's with VYALEV and tavapadon, as Jeff mentioned... In fact, we expect to be the largest neuroscience company in the industry next year.”

In context

“orce expansions on that front. And certainly, Roopal and I both highlighted the study versus topiramate. Now topiramate basically is 40% to 50% of all the generics in the preventative space. And so we will also be assessing on whether or not more representation might enable QULIPTA to basically start to power forward over the long-range plan. But that approach is underway. But at a macro level, we certainly want to continue to invest into the neuroscience growth rates that we're seeing. Robert A. Michael: This is Rob. I mean I think it's an important question because we are obviously going to fully invest in neuroscience. It's our second largest therapeutic area. It's the fastest growing in our portfolio. In fact, we expect to be the largest neuroscience company in the industry next year. We clearly have very strong positions in psych and migraine and emerging leadership position in Parkinson's with VYALEV and tavapadon, as Jeff mentioned. And we also have an opportunity to drive advancement in Alzheimer's treatment through the Aliada platform. You've seen us over the course of the last several years, invest in external innovation. We've highlighted the Gedeon Richter discovery collaboration in psych, the Gilgamesh opportunity that we entered into last year in mood disorders. I mentioned Aliada, very excited about that next-generation A-beta antibody in Alzheimer's, again, with a unique shuttle platform. And then as I discussed earlier today, the siRNA opportunity with ADARx will play a role in neuroscience as well. And so we are fully investing in neuroscience. We look forward to maintaining our leadership position there. It's obviously performing exceptionally well. You saw across the board. Every brand exceeded expectations in neuroscience this quarter, and we're going to keep fueling that engine. Elizabet”